December 2, 2024 - 22:16
In a significant leadership move, DELFI Diagnostics has announced the appointment of Dr. Amoolya Singh as its new Chief Technology Officer. Dr. Singh brings a wealth of experience in the field of diagnostics and biotechnology, which will be instrumental in advancing the company’s mission to revolutionize cancer detection through innovative blood-based liquid biopsy tests.
With a focus on enhancing early cancer detection, DELFI Diagnostics aims to make these critical tests more accessible to patients. Dr. Singh's expertise in technology development and her commitment to improving healthcare outcomes are expected to play a pivotal role in driving the company’s research and development efforts. Her previous work has significantly contributed to advancements in diagnostic technologies, making her an ideal fit for this position.
As the company continues to push the boundaries of what is possible in cancer diagnostics, Dr. Singh’s leadership is anticipated to foster innovation and accelerate the development of new solutions that can ultimately save lives.
